Plivensia FDA Approval Status
FDA Approved: No
Brand name: Plivensia
Generic name: sirukumab
Company: Johnson & Johnson Innovative Medicine
Treatment for: Rheumatoid Arthritis
Plivensia (sirukumab) is a human anti-interleukin-6 monoclonal antibody in development for the treatment of rheumatoid arthritis.
Development timeline for Plivensia
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.